Stockholm:HNSA

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance

Retrieved on:

Tuesday, April 2, 2024

Sarepta Therapeutics, Interest, Growth, CFO, CCO, CSO, Person

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.

Key Points:

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.
Søren Tulstrup, President and CEO, Hansa Biopharma, said: "Q1 represents a strong start to the year with solid product sales for the second quarter in a row and the best IDEFIRIX® product sales recorded in a quarter.
The Company will publish Q1 2024 results on April 18, 2024.
The information was submitted for publication, through the contact persons set out below, at 07:00: CET on April 2, 2024.

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance

Retrieved on:

Tuesday, April 2, 2024

Sarepta Therapeutics, Interest, Growth, CFO, CCO, CSO, Person

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.

Key Points:

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.
Søren Tulstrup, President and CEO, Hansa Biopharma, said: "Q1 represents a strong start to the year with solid product sales for the second quarter in a row and the best IDEFIRIX® product sales recorded in a quarter.
The Company will publish Q1 2024 results on April 18, 2024.
The information was submitted for publication, through the contact persons set out below, at 07:00: CET on April 2, 2024.

Hansa Biopharma publishes 2023 Annual and Sustainability Reports

Retrieved on:

Thursday, March 21, 2024

LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports. In 2023, the company made solid progress in both Commercial and R&D priorities and continued its journey to become a default sustainable organization.

Key Points:

LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports.
Peter Nicklin, Chairman of the Board, Hansa Biopharma, said: "2023 was another important year for Hansa Biopharma.
Søren Tulstrup, President and CEO, Hansa Biopharma, said: "In 2023, the Company's focus remained firmly on advancing cutting-edge science and delivering new treatments in areas of high unmet need.
This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.

Hansa Biopharma publishes 2023 Annual and Sustainability Reports

Retrieved on:

Thursday, March 21, 2024

LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports. In 2023, the company made solid progress in both Commercial and R&D priorities and continued its journey to become a default sustainable organization.

Key Points:

LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports.
Peter Nicklin, Chairman of the Board, Hansa Biopharma, said: "2023 was another important year for Hansa Biopharma.
Søren Tulstrup, President and CEO, Hansa Biopharma, said: "In 2023, the Company's focus remained firmly on advancing cutting-edge science and delivering new treatments in areas of high unmet need.
This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.

Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer

Retrieved on:

Thursday, February 22, 2024

CFO, MD, SVP, Growth, Executive Committee, Hansa, University, Therapy, Information services, Management

LUND, Sweden, Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024.

Key Points:

LUND, Sweden, Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024.
As CFO, Mr. Ballantyne will be responsible for developing and implementing the Company's corporate financial strategy and activities including financial reporting and investor relations (IR).
Most recently, Mr. Ballantyne was Senior Vice President, Chief Financial Officer at Gain Therapeutics, Inc. (Gain), a US based biotech company.
Søren Tulstrup, President and CEO, Hansa Biopharma said, "I am thrilled to welcome Evan to Hansa Biopharma at this pivotal and exciting time.

Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer

Retrieved on:

Thursday, February 22, 2024

CFO, MD, SVP, Growth, Executive Committee, Hansa, University, Therapy, Information services, Management

LUND, Sweden, Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024.

Key Points:

LUND, Sweden, Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024.
As CFO, Mr. Ballantyne will be responsible for developing and implementing the Company's corporate financial strategy and activities including financial reporting and investor relations (IR).
Most recently, Mr. Ballantyne was Senior Vice President, Chief Financial Officer at Gain Therapeutics, Inc. (Gain), a US based biotech company.
Søren Tulstrup, President and CEO, Hansa Biopharma said, "I am thrilled to welcome Evan to Hansa Biopharma at this pivotal and exciting time.

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

Retrieved on:

Saturday, January 6, 2024

Marketing, Repeat, Conference, Partnership, Kidney transplantation, Trial of the century, Sarepta Therapeutics, DMD, Imlifidase, Growth, ANCA, Enzyme, Patient, Duchenne muscular dystrophy, Hansa, Immunoglobulin G, Neutron, Pharmaceutical industry

Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.

Key Points:

Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.
We also continue to expand access to imlifidase for highly sensitized kidney transplant patients through a new commercial partnership with NewBridge in the MENA region.
Management will be available for meetings in San Francisco during the J.P. Morgan Conference week, January 8-11, 2024.
Susan Noonan is coordinating the schedule on behalf of Hansa Biopharma and can be reached at [email protected] .

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

Retrieved on:

Saturday, January 6, 2024

Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.

Key Points:

Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.
We also continue to expand access to imlifidase for highly sensitized kidney transplant patients through a new commercial partnership with NewBridge in the MENA region.
Management will be available for meetings in San Francisco during the J.P. Morgan Conference week, January 8-11, 2024.
Susan Noonan is coordinating the schedule on behalf of Hansa Biopharma and can be reached at [email protected] .

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

Retrieved on:

Thursday, December 14, 2023

DSA, Patient, AMR, Hansa, Imlifidase, Vaccine, Medical imaging

LUND, Sweden, Dec. 14, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody mediated rejection (AMR) episodes following a kidney transplant demonstrating that imlifidase significantly reduced donor-specific antibodies (DSAs) within the first five days of treatment.

Key Points:

In the trial, the primary endpoint was the maximum reduction in DSA level at any time point during the 5 days following the start of treatment.
Patients treated with imlifidase demonstrated a statistically significant reduction of DSAs by 94.4% compared to a 35.6% (p-value:
The secondary endpoint investigated overall kidney function following treatment.
This is an important step in understanding how imlifidase may benefit patients with AMR.

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

Retrieved on:

Thursday, December 14, 2023

DSA, Patient, AMR, Hansa, Imlifidase, Vaccine, Medical imaging

LUND, Sweden, Dec. 14, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody mediated rejection (AMR) episodes following a kidney transplant demonstrating that imlifidase significantly reduced donor-specific antibodies (DSAs) within the first five days of treatment.

Key Points:

In the trial, the primary endpoint was the maximum reduction in DSA level at any time point during the 5 days following the start of treatment.
Patients treated with imlifidase demonstrated a statistically significant reduction of DSAs by 94.4% compared to a 35.6% (p-value:
The secondary endpoint investigated overall kidney function following treatment.
This is an important step in understanding how imlifidase may benefit patients with AMR.